Clinical Trial

Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine

Name: Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine — clinical trial record (NCT07418372)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a randomized, double-blinded, parallel-controlled phase I/II clinical trial to evaluate the safety and preliminary immunogenicity of the Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (reduced antigen content) in subjects aged 6 years and above.

Trial Details

NCT Number	NCT07418372
Lead Sponsor	Institute of Medical Biology, Chinese Academy of Medical Sciences
Conditions	Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria, Pertussis, Pertussis Vaccines
Enrollment	660 participants
Start Date	2026-03-12
Primary Completion	2026-08-31 (estimated)
Study Completion	2027-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-18